Small Cell Lung Cancer

1.American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society. 2019. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf.

 

2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.J Clin Oncol. 2006;24(28):4539-4544.

 

3. Breitling LP, Rinke A, Gress TM. Recent survival trends in high-grade neuroendocrine neoplasms and lung cancer. Neuroendocrinology. 2020;110(3-4):225-233.

 

4. Abdel-Rahman O. Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis. Clin Respir J. 2018;12(3):1093-1099.

 

5.Globocan: https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-

sheet.pdf

 

6.ESMO:https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-lung-and-chest-

tumours

 

7.NCCN: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462

 

8.NICE : https://www.nice.org.uk/what-nice-does/our-guidance/about-nice-guidelines

 

9.Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small    

cell lung carcinoma: a prospective study. Neurology 2015;85(3):235-239.

 

10.Seute T, Leffers P, ten Velde GP, et al. Detection of brain metastases from small cell lung 

cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008;112(8):1827-1834.

 

11.Martucci F, Pascale M, Valli MC, et al. Impact of (18)F-FDG PET/CT in staging patients

with small cell lung cancer: a systematic review and meta-analysis. Front Med (Lausanne).  2019;6:336.

 

12.Manoharan P, Salem A, Mistry H, et al. (18)F-Fludeoxyglucose PET/CT in SCLC: 

analysis of the CONVERT randomized controlled trial. J Thorac Oncol. 2019;14(7):1296-1305. 

 

13.Qin J, Lu H. Combined small-cell lung carcinoma. Onco Targets Ther  

2018;11:3505–3511.

 

14.Zhao X, Kallakury B, Chahine JJ, et al. Surgical resection of SCLC: prognostic factors 

and the tumor microenvironment. J Thorac Oncol. 2019;14(5):914-923.

 

15.Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: 

proposed definition. Lung Cancer. 2005;49(1):25-33.

 

16.Ernani V, Ganti AK. Surgery for limited-stage small cell lung cancer: ready for prime-

time? J Thorac Dis. 2017;9(10):3576-3578.

 

17.Stinchcombe TE. Current treatments for surgically resectable, limitedstage,

and extensive-stage small cell lung cancer. Oncologist. 2017;22(12):1510-1517.

 

18.Yang CF, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population-

based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol. 2016;34(10):1057-1064.

 

19.Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of 

etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30(1):23-36.

 

20.Karam I, Jiang SY, Khaira M, et al. Outcomes of small cell lung cancer patients treatedwith cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol. 2015;38(1):51-54.

 

            21. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemo radiotherapy in patients with limited-stage small cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116-1125.

 

22. Gomes F, Faivre-Finn C, Mistry H, et al. Safety of G-CSF with concurrent

chemo-radiotherapy in limited-stage small cell lung cancerdsecondary

analysis of the randomised phase 3 CONVERT trial. Lung

Cancer. 2021;153:165-170.

 

23.             Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4): 265-271.

 

24.De Ruysscher D, Lueza B, Le Péchoux C, et al. Impact of thoracic radiotherapy timing in

limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10): 1818-1828.

 

25.Lu H, Fang L, Wang X, et al. A meta-analysis of randomized controlled trials 

comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol. 2014;2(5):805-810.

 

26.             Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol. 1987;5(4):592-600.

 

            27.Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higherdose

prophylactic cranial irradiation (PCI) in patients with limitedstage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol.2009;10(5):467-474.

 

           28.Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation

for patients with small-cell lung cancer in complete remission.

Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl

J Med. 1999;341(7):476-484.

 

 

29.Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663-671.

 

30.Liu ZL, Wang B, Liu JZ, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: a meta-analysis. J Cancer Res Ther. 2018;14(Supplement):S1076-S1083.

 

31. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized,

phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2044-2051.

 

32.Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poorprognosis small cell lung cancer. Thorax. 2009;64(1):75-80.

 

33.Slotman BJ, van Tinteren H, Praag JO, et al. Radiotherapy for extensive

stage small-cell lung cancerdauthors’ reply. Lancet. 2015;385(9975):1292-1293.

 

34.Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation

in extensive small-cell lung cancer. N Engl J Med. 2007;357(7): 664-672.

 

35.Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17(7):2092-2099.

 

36.Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy

of second-line chemotherapy in sensitive and refractory smallcell lung cancer. J Thorac Oncol. 2012;7(5):866-872.

 

37.von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide,

doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-667.

 

38.Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23(9):1409-1411.